Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
$2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals. - 25 Advancement Developments in Biotechnology
- 3Federal judge upholds Hawaii's new climate change tax on cruise passengers
- 4Figure out How to Clean and Really focus on Your Lab Jewel
- 5The Extraordinary Excursion of Dental Embed Innovation
- Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks
- NASA funds new tech for upcoming 'Super Hubble' to search for alien life: 'We intend to move with urgency'
- Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- Manual for Tracking down the Nearby Business sectors and Marketplaces
- The most effective method to Begin Your Excursion in Gold Venture
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- Single women risk rape and exploitation in search for better life in Europe
- Toddler diagnosed with cancer makes remarkable recovery after aggressive treatment
- Famous Places to get-away for Americans
